MITOMYCIN-OLIGONUCLEOTIDES FOR VASCULAR THERAPY

Information

  • Research Project
  • 2228718
  • ApplicationId
    2228718
  • Core Project Number
    R43HL051778
  • Full Project Number
    1R43HL051778-01
  • Serial Number
    51778
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1994 - 30 years ago
  • Project End Date
    5/31/1995 - 29 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1994 - 30 years ago
  • Budget End Date
    5/31/1995 - 29 years ago
  • Fiscal Year
    1994
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/15/1994 - 30 years ago

MITOMYCIN-OLIGONUCLEOTIDES FOR VASCULAR THERAPY

The research objective is synthesis of a conjugate of mitomycin C to an antisense phosphorothioate nucleotide targeted to proliferating smooth muscle cells responsible for arterial occlusion. This would provide a novel approach to the prevention of restenosis, for which there is currently no effective medicinal intervention available. Mitomycins will be derivatized with a linking group to permit covalent attachment to the 5' end of end of an antisense oligonucleotide, either while attached to the solid support, or after cleavage of the oligonucleotide from the solid support. Compounds will be assayed in a cell culture assay to evaluate the effectiveness of such agents compared to either of the components individually or co-administered,to determine if synergistic activity against cell proliferation is achieved. In principle, we envisage the antisense oligonucleotide hybridizing with RNA in a smooth muscle cell and permitting the attached mitomycin C to covalently modify an adjacent guanine base, thereby preventing transcription of the target gene, and preventing cell cycling. Such permanent modification may be anticipated to be more effective than oligonucleotide hybridization alone, while operating at a sub-toxic dose of mitomycin C. The site of the mitomycin- oligonucleotide conjugate bonding to RNA in vitro for promising drug candidates will be verified by melting point (Tm) measurements prior to drug activation and by the reverse transcriptase assay after drug activation.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    TEXAS BIOTECHNOLOGY CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    HOUSTON
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    77030
  • Organization District
    UNITED STATES